Using ICG imaging to improve surgery for giant cell tumors of bone

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the use of indocyanine green (ICG) fluorescence imaging during intralesional curettage for patients with giant cell tumors of bone in the limbs. The goal is to determine if this imaging technique can help identify small residual tumors that may lead to recurrence after surgery. By providing real-time visual feedback, the study aims to enhance the surgeon's ability to remove all tumor tissue effectively. This approach could potentially lower the recurrence rate associated with traditional surgical methods.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. . Aged 18-65.
2. Biopsy confirmed giant cell tumor of bone.
3. The lesions located in the limbs.
4. This operation is the initial treatment.
5. Denosumab and diphosphonates are not used before surgery.
6. Planned operation is intralesional curettage and filling bone defects with bone cement.
7. Preoperative bone scan and thin layer (layer thickness ≤3.5mm) chest CT plain scan confirmed that the lesion is a single occurrence without metastasis.
8. Subjects fully understand the benefits and risks of this experiment and are still willing to participate and sign the informed consent.

Exclusion Criteria:

1. . Known allergy to iodine contrast, indocyanine green or bone cement.
2. . Severe hepatic and renal insufficiency.
3. . During pregnancy or lactation.
4. . Have other malignant tumors and are receiving related medical treatment.

Where it's running

• Peking University People's Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Han Wang, MD
• Email: wh23333@126.com
• Phone: +86 13520170664

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TRACP-5b test to help diagnose and monitor giant cell tumor of bone

  This study tests whether a blood marker, TRACP-5b, can help diagnose and track giant cell tumor of bone in adults.

  Recruiting St. Anne's University Hospital Brno, Czech Republic · Brno · NCT07609277

• Indocyanine green fluorescence to find leftover giant cell tumor tissue during surgery

  We will try a dye called indocyanine green with near-infrared imaging during surgery to help surgeons spot any remaining giant cell tumor tissue in people having surgery for GCTB.

  Recruiting Phase 4 Shanghai Jiao Tong University Affiliated Sixth People's Hospital · Shanghai · NCT07315828

• PROMIS questionnaires and smartphone mobility tracking after sarcoma surgery

  This project tests whether PROMIS questionnaires together with a new smartphone app can track recovery and mobility in adults undergoing surgery for sarcoma or giant cell tumor of bone.

  Recruiting at 2 sites University of Calgary · Phoenix, Arizona and 3 other locations · NCT07227961

• Using zoledronic acid-loaded bone cement to reduce recurrence of giant cell bone tumors after surgery

  This study tests if using a special bone cement with a drug can help prevent giant cell bone tumors from coming back after surgery, compared to regular bone cement.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou · NCT05595603

• Using bisphosphonate to reduce tumor recurrence in bone tumors

  This study is testing if using a special bone cement with bisphosphonate during surgery can help prevent giant cell tumors in bones from coming back and improve recovery compared to regular surgery alone.

  Recruiting at 12 sites Phase 3 St. Louis University · Los Angeles, California and 15 other locations · NCT03295981

• Pimicotinib for Japanese people with tenosynovial giant cell tumor (J-MANEUVER)

  This trial will test whether pimicotinib is safe, reaches effective blood levels, and improves symptoms in Japanese participants with unresectable tenosynovial giant cell tumor.

  Recruiting at 4 sites Phase 2 Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Chūōku and 3 other locations · NCT07499362

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.